Enliven Therapeutics Inc
ELVN
Company Profile
Business description
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Contact
6200 Lookout Road
BoulderCO80301
USAT: +1 720 647-8519
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
62
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,287.90 | 84.00 | 1.02% |
| CAC 40 | 7,574.85 | 1.09 | 0.01% |
| DAX 40 | 22,363.21 | 91.54 | 0.41% |
| Dow JONES (US) | 40,227.59 | 114.09 | 0.28% |
| FTSE 100 | 8,405.60 | 11.74 | -0.14% |
| HKSE | 21,988.08 | 16.12 | 0.07% |
| NASDAQ | 17,366.13 | 16.81 | -0.10% |
| Nikkei 225 | 35,839.99 | 134.25 | 0.38% |
| NZX 50 Index | 12,025.45 | 73.44 | -0.61% |
| S&P 500 | 5,528.75 | 3.54 | 0.06% |
| S&P/ASX 200 | 8,070.60 | 73.50 | 0.92% |
| SSE Composite Index | 3,286.65 | 1.76 | -0.05% |